Latest Servier Stories

SAN DIEGO and PARIS, April 30, 2013 /PRNewswire/ -- Afraxis, Inc. ("Afraxis") and Institut de Recherches Servier ("Servier") announced a non-exclusive platform collaboration using Afraxis' Enhanced Spine Platform (ESP) Technology for the discovery of drugs to treat central nervous system (CNS) disorders. Afraxis' ESP Technology rapidly assesses complex neural networks to evaluate preclinical efficacy and safety in CNS disorders. The technology quantifies and characterizes the...

ROCKVILLE, Md. and SURESNES, France, Sept. 20, 2012 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately-held pharmaceutical company, announced today that they have entered into an option agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART(TM)) products directed at three undisclosed tumor targets. MacroGenics' DART...

BRAY, Ireland, December 20, 2011 /PRNewswire/ -- Osteologix Holdings, PLC ("Osteologix" or the "Company") declared a dividend of Euro 0.06 per sharepayable to shareholders of record on December 19, 2011. The payment date will be February 15, 2012. The payment date is being delayed to allow time for certain Irish Dividend WithholdingTax ("DWT") exemption forms to be returned to the Company by shareholders prior to dividend payment. Shareholders who are not Irish...

ROCKVILLE, Maryland and SURESNES, France, Dec. 1, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately-held pharmaceutical company, announced today that they have entered into an option for a license agreement for the development and commercialization of MGA271, MacroGenics' proprietary product candidate. MGA271 is a first-in-class, Fc-optimized monoclonal...

SURESNES, France and MONTRÉAL, QC, Nov. 8, 2011 /PRNewswire/ - Les Laboratoires Servier, France (Servier) and Prognomix Inc., Canada  (Prognomix) announced today that they have entered into a research and development agreement aimed at identifying novel targets as part of programs meant to develop innovative type 2 diabetes and metabolic disease treatment. This collaboration will rest on the discovery platform developed by Prognomix. This platform comprises genomic and...

NEW YORK, and NEUILLY, France, Aug. 9, 2011 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. (Intercept) and Les Laboratoires Servier (Servier) today announced that they have entered into a worldwide ex-U.S. and Japan agreement for the discovery and development of novel TGR5 agonists for the treatment of type 2 diabetes and other metabolic indications. The collaboration will leverage Intercept's drug discovery platform based on its proprietary bile acid analog chemistry and expertise...

DUBLIN, August 5, 2011 /PRNewswire/ -- Osteologix Holdings, PLC ("Osteologix" or the "Company") stated that its previously announced plans to consolidate its operations in Ireland have been completed. All operations at the former location in Virginia have ceased. Its former parent, Osteologix, Inc. has been dissolved and all former shareholders as of the exchange date of July 26, 2011 will receive an equal number of shares of Osteologix Holdings PLC. Shares of the Company...

SUNNYVALE, Calif., April 26, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has received a $7 million milestone payment for its histone deacetylase (HDAC) inhibitor, PCI-24781 / S 78454 from Les Laboratoires Servier ("Servier") based on an ex-US collaboration agreement signed in April of 2009. Over the past two years Servier has engaged in several exploratory Phase I/II trials in solid tumors and hematologic malignancies. Servier is now focused on its...

FRANKFURT, Germany and LAUSANNE, Switzerland and PARIS, June 14, 2010 /PRNewswire-FirstCall/ -- IMIDIA ("Innovative Medicines Initiative for Diabetes"), a public private consortium funded by the Innovative Medicines Initiative (IMI), announced today the launch of a project focusing on pancreatic islet cell function and survival. Academia, biotech and pharma industry have joined forces to develop biomarkers and tools to pave the way for improved disease management and ultimately provide...

SUNNYVALE, Calif., Feb 11 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its second fiscal quarter ended December 31, 2009. Upon the completion of a drug supply agreement with Servier in the quarter ended December 31, 2009, the company began recognizing revenue under GAAP from its collaboration agreement with Servier, which was entered into in April 2009. Total revenue recognized under GAAP in our most recent quarter was $4.7 million, of...